Goserelin 10.8mg implant pre-filled syringes

ObjectiveTo evaluate the effectiveness of goserelin sustained-release microspheres versus sustained-release implants for androgen deprivation therapy (ADT) in patients with prostate cancer in a real-world setting, and to compare their safety profiles by integrating evidence from published studies.MethodsThis retrospective study included 87 patients with prostate cancer who received goserelin-based ADT at Peking University Cancer Hospital Inner Mongolia Hospital between August 2024 and September 2025. Forty-four patients received goserelin sustained-release microspheres, and 43 received sustained-release implants. During the 12-week observation period, patients received median administrations of three and one, respectively, corresponding to comparable ADT exposure. Analyses were patient-based. The primary endpoint was the proportion achieving total prostate-specific antigen (TPSA) ResultsMedian age was 72 years, and median follow-up was 85 days. Baseline disease stage differed between groups, with more metastatic disease in the implant group. At D29, TPSA response rates were 81.8% and 95.2% in the microsphere and implant groups, respectively. At D85, rates were 86.4% and 93.0%, meeting the prespecified non-inferiority criterion. Sensitivity analyses using TPSA ConclusionsGoserelin sustained-release microspheres demonstrated comparable real-world biochemical activity to sustained-release implants over matched 12-week ADT exposure. Although early PSA differences and baseline disease-stage imbalance warrant consideration, integrated evidence supports goserelin microspheres as an alternative ADT formulation with a manageable safety profile.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261327915.

Abstract licence: CC BY